Skip to content

Duloxetine: US FDA label indications

US FDA labelNot medical advice

The product name above is taken from the label's own indications text; the source record has no brand or generic name field.

Indications and usage (label excerpt)

1 INDICATIONS AND USAGE Duloxetine is a serotonin and norepinephrine reuptake inhibitor (SNRI) indicated for: Major Depressive Disorder (MDD) ( 1.1 ) Generalized Anxiety Disorder (GAD) ( 1.2 ) Diabetic Peripheral Neuropathic Pain (DPNP) ( 1.3 ) Fibromyalgia (FM) ( 1.4 ) Chronic Musculoskeletal Pain ( 1.5 ) 1.1 Major Depressive Disorder Duloxetine is indicated for the treatment of major depressive disorder (MDD). The efficacy of duloxetine was established in four short-term and one maintenance trial in adults [see Clinical Studies ( 14.1 )] . A major depressive episode (DSM-IV) implies a prominent and relatively persistent (nearly every day for at least 2 weeks) depressed or dysphoric mood that usually interferes with daily functioning, and includes at least 5 of the following 9 symptoms: depressed mood, loss of interest in usual activities, significant change in weight and/or appetite, insomnia or hypersomnia, psychomotor agitation or retardation, increased fatigue, feelings of guilt or worthlessness, slowed thinking or impaired concentration, or a suicide attempt or suicidal ideation. 1.2 Generalized Anxiety Disorder Duloxetine is indicated for the treatment of generalized anxiety disorder (GAD). The efficacy of duloxetine was established in three short-term trials and one maintenance trial in adults [see Clinical Studies ( 14.2 )] . Generalized anxiety disorder is defined by the DSM-IV as excessive anxiety and worry, present more days than not, for at least 6 months. The ex…

Warnings (label excerpt)

5 WARNINGS AND PRECAUTIONS Suicidality: Monitor for clinical worsening and suicide risk ( 5.1 ) Hepatotoxicity: Hepatic failure, sometimes fatal, has been reported in patients treated with duloxetine. Duloxetine should be discontinued in patients who develop jaundice or other evidence of clinically significant liver dysfunction and should not be resumed unless another cause can be established. Duloxetine should not be prescribed to patients with substantial alcohol use or evidence of chronic liver disease ( 5.2 ) Orthostatic Hypotension and Syncope: Cases have been reported with duloxetine therapy ( 5.3 ) Serotonin Syndrome: Serotonin syndrome has been reported with SSRIs and SNRIs, including with duloxetine, both when taken alone, but especially when co-administered with other serotonergic agents (including triptans, tricyclic antidepressants, fentanyl, lithium, tramadol, tryptophan, buspirone and St. John's Wort). If such symptoms occur, discontinue duloxetine and initiate supportive…

Excerpts are shortened. Read the full label, and ask a pharmacist or prescriber about any medicine. Full label on DailyMed(opens in a new tab) For products sold in Canada, see the Health Canada Drug Product Database(opens in a new tab).

Trials whose interventions mention this drug

Canadian trials first. A match on the drug name does not mean the trial studied this specific product.

41 trials, recruiting first
PhaseCountries
Personalized Analgesia Through Central Nervous System Engagement to Unlock Performance
NCT07759336
Not yet recruitingPhase 4United StatesBenedict Alter2026-08
Algorithm-informed Decision-making to Advance Pain Treatment
NCT07731750
RecruitingNot applicableUnited StatesUniversity of Michigan2026-07-23
Duloxetine to Prevent Chronic Postsurgical Pain After Inguinal Hernia Repair in Patients at High Risk
NCT06606067
Active, not recruitingPhase 3SpainParc de Salut Mar2024-09-03
Focal Microvibration and Chronic Lumbosacral Radicular Pain
NCT06301061
Unknown statusNot applicableFederico II University2024-04-01
Pain Relieving Potentials of Combination of Oral Duloxetine and Intravenous Magnesium Sulphate in Post Mastectomy Pain
NCT06087211
CompletedNot applicableEgyptNational Cancer Institute, Egypt2023-10-10
Duloxetine Impact on Postoperative Pain Control and Outcomes
NCT05611749
TerminatedPhase 2United StatesScripps Health2023-05-30
The BEST Trial: Biomarkers for Evaluating Spine Treatments
NCT05396014
CompletedPhase 4United StatesUniversity of North Carolina, Chapel Hill2022-09-12
Duloxetine on Bone Metabolism
NCT05550506
Unknown statusTurkey (Türkiye)Cukurova University2022-07-27
Efficacy of Duloxetine in Conjunction With Tramadol for Chronic Cancer Pain
NCT05311774
CompletedNot applicableEgyptAssiut University2022-04-01
The Back Pain Consortium Research Program Study
NCT04870957
CompletedPhase 4United StatesUniversity of Michigan2021-06-09
Esketamine Adjuvant Therapy for Patients With Chronic Visceral Pain Comorbid Major Depressive Disorder
NCT04847245
Unknown statusNot applicablePeking University2021-05-01
Duloxetine vs Pregabalin for Thoracotomy Pain
NCT04782310
Unknown statusPhase 4EgyptCairo University2021-03-10
Pain Response Evaluation of a Combined Intervention to Cope Effectively
NCT04395001
CompletedPhase 4United StatesWake Forest University Health Sciences2021-02-24
Duloxetine As an Analgesic in Patients Without Central Sensitivity After Same Sitting Bilateral Total Knee Arthroplasty
NCT06837012
CompletedPhase 4IndiaOrthopaedic Arthroscopy Knee and Shoulder Clinic2021-01-01
The Effect of Transcutaneous Posterior Tibial Nerve Stimulation in Patients With Fibromyalgia
NCT05937711
CompletedNot applicableTurkey (Türkiye)Ilker Fatih Sari2020-11-02
Duloxetine Combined With Intra-articular Injection of Corticosteroid and Hyaluronic Acid Reduces Pain in the Treatment of Knee Osteoarthritis Patients
NCT04117893
CompletedPhase 4ChinaBeijing Tiantan Hospital2019-10-01
Comparing Effectiveness of Duloxetine and Desipramine in Patients With Chronic Pain: A Pragmatic Trial Using Point of Care Randomization
NCT03548454
CompletedPhase 4United StatesStanford University2018-09-20
Effect of Combined Morphine and Duloxetine on Chronic Pain
NCT03249558
CompletedPhase 4United StatesMassachusetts General Hospital2018-03-12
Altering The Transition From Acute to Chronic Pain (ATTAC-Pain)
NCT03315533
CompletedPhase 2United StatesRhode Island Hospital2018-01-19
Determination of the Antidepressant Duloxetine in Plasma to Improve the Knowledge of the Analgesic Action of Antidepressants on Chronic Neuropathic Pain
NCT02846701
CompletedPhase 4University Hospital, Strasbourg, France2016-11-17
Shifting Pain Modulation From Pro-to Anti-nociceptive
NCT02672202
TerminatedNot applicableRambam Health Care Campus2016-02
A Policy Relevant US Trauma Care System Pragmatic Trial for PTSD and Comorbidity
NCT02655354
CompletedNot applicableUnited StatesUniversity of Washington2015-10
Imaging Pain Relief in Osteoarthritis
NCT02208778
CompletedPhase 4United KingdomUniversity of Nottingham2014-12
A Study of Duloxetine (LY248686) in Participants With Chronic Osteoarthritis and Knee Pain in Japan
NCT02248480
CompletedPhase 3JapanEli Lilly and Company2014-10
Does Duloxetine Reduce Chronic Pain After Total Knee Arthroplasty?
NCT02307305
Unknown statusPhase 2South KoreaHanyang University Seoul Hospital2014-08
Mechanistic Study of Duloxetine in Breast Cancer Patients With Chronic Pain
NCT01912612
CompletedPhase 2United StatesUniversity of Michigan Rogel Cancer Center2013-10-30
An Open Label Extension Study of Duloxetine (LY248686) in Participants With Chronic Low Back Pain
NCT01914666
CompletedPhase 3JapanEli Lilly and Company2013-09
A Study of Duloxetine in Participants With Chronic Pain Due to Osteoarthritis in China
NCT01931475
CompletedPhase 3ChinaEli Lilly and Company2013-09
A Study of Duloxetine (LY248686) in Participants With Chronic Low Back Pain
NCT01855919
CompletedPhase 3JapanEli Lilly and Company2013-05
Duloxetine for the Treatment of Chronic Pelvic Pain
NCT01451606
TerminatedPhase 4United StatesUniversity of Maryland, Baltimore2011-07-11
Comparison of the Efficacy of Duloxetine With Placebo in Patients With Chronic Low Back Pain With a Radicular Component
NCT01166048
CompletedPhase 4AustriaMedical University of Vienna2010-05
A Study of Single Dose Pain Therapy in Patients With Painful Diabetic Neuropathy (0000-115)
NCT00837941
WithdrawnPhase 2Merck Sharp & Dohme LLC2009-04
A Study for Patient With Chronic Low Back Pain
NCT00767806
CompletedPhase 3Brazil, Germany, Netherlands, Poland...Eli Lilly and Company2008-09
Three Way Interaction Between Gabapentin, Duloxetine, and Donepezil in Patients With Diabetic Neuropathy
NCT00619983
TerminatedPhase 4United StatesWake Forest University2008-02
Duloxetine Treatment of Major Depression and Chronic Low Back Pain For Older Adults
NCT00696293
CompletedPhase 4United StatesUniversity of Pittsburgh2007-05
Duloxetine Versus Placebo in Chronic Low Back Pain
NCT00424593
CompletedPhase 3Brazil, France, Germany, Mexico...Eli Lilly and Company2007-01
Open Label Study of Duloxetine for the Treatment of Phantom Limb Pain
NCT00425230
TerminatedNot applicableUnited StatesBaylor College of Medicine2007-01
Pilot, Opened, Randomized Clinical Trial to Assess the Efficacy of Duloxetine in the Treatment of Fibromialgy in Patients With Infection by HIV 1+
NCT00552682
CompletedPhase 3SpainGermans Trias i Pujol Hospital2007-01
Duloxetine Versus Placebo in Chronic Low Back Pain
NCT00408876
CompletedPhase 3United StatesEli Lilly and Company2006-12
Imaging Study of Chronic Low Back Pain in Patients Taking Pain Medication
NCT00388414
CompletedNot applicableUnited StatesStanford University2006-09
A Study for the Treatment of Painful Diabetic Neuropathy
NCT00058968
CompletedPhase 3United StatesEli Lilly and Company2002-10

Source: openFDA drug label (US FDA), snapshot October 2026. Not a Health Canada Product Monograph.